Showing results (61-70 of 82) with videos related to
Sort By:
Pageof 9
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.Oncoimmunology|January 18, 2021
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS studyFabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.The European Respiratory Journal|August 12, 2017
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsMyriam Delaunay, Jacques Cadranel, Amélie Lusque, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.Oncoimmunology|April 7, 2025
Surrogate markers of intestinal dysfunction associated with survival in advanced cancersRoxanne Birebent, Damien Drubay, Carolina Alves Costa Silva, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung CancerGlenwood D Goss, Gail E Darling, Virginie Westeel, et al.Pageof 9